COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 341: Articles 3401-3410  | Next

Relative vaccine effectiveness of a CoronaVac booster dose in preventing symptomatic SARS-CoV-2 infection among healthcare workers during an Omicron period in Azerbaijan, January-August 2022
Finci, I., Rojas Castro, M. Y., Seyidov, N., Mehdiyev, S., McKnight, C. J., Muehlemann, B., Drosten, C., Duca, L., Pebody, R., Kissling, E., Katz, M. A., Hagverdiyev, G.
10.1101/2023.10.20.23297300 — Posted: 2023-10-20
Divergent spike mutations impact the activation of the fusion core in Delta and Omicronvariants of SARS-CoV-2
Dutta, M., Voth, G. A.
10.1101/2023.10.19.563184 — Posted: 2023-10-20
FAKHRAVAC and BBIBP-CorV vaccine seeds' binding to angiotensin-converting enzyme 2: A comparative molecular dynamics study
Setareh, S., Rad, I., Meghdadi, J., Khodayari, K., Karimi Rahjerdi, A.
10.1101/2023.10.19.563051 — Posted: 2023-10-20
Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by PBR28 PET correlates with vascular disease measures
VanElzakker, M. B., Bues, H. F., Brusaferri, L., Kim, M., Saadi, D., Ratai, E.-M., Dougherty, D. D., Loggia, M. L.
10.1101/2023.10.19.563117 — Posted: 2023-10-20
SARS-CoV-2 lineage-specific disease symptoms and disease severity in Sao Caetano do Sul city, Brazil
Sales, F. C. S., Prete, C. A., Abade, L., Buss, L. F., Candido, D. S., Claro, I. M., Moreira, F. R. R., Manulli, E. R., Capuani, L., Silva, C. A. M., Oliveira, B. A., Coletti, T., Paiao, H. G. O., Costa, S. F., Correa, M. C. M., Leal, F. E., Parag, K. V., Nascimento, V. H., Faria, N. R., Sabino, E. C.
10.1101/2023.10.19.23297252 — Posted: 2023-10-20
Excess deaths in China during SARS-CoV-2 viral waves in 2022-2023
Jha, P., Brown, P. E., Lam, T., Morawski, E., Reid, A.
10.1101/2023.10.18.23297204 — Posted: 2023-10-19
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants.
Poulakou, G., Royer, P.-J., Evgeniev, N., Evanno, G., Shneiker, F., Marcelin, A.-G., Vanhove, B., Duvaux, O., Marot, S., Calvez, V.
10.1101/2023.10.09.23296726 — Posted: 2023-10-19
Association between common adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations in a population-based prospective cohort study in the Netherlands
Holwerda, M. R., Hoeve, C. E., Huiberts, A. J., den Hartog, G., de Melker, H. E., van den Hof, S., Knol, M.
10.1101/2023.10.19.23297194 — Posted: 2023-10-19
COVID-19 cases associated with testing policies in 34 highly democratic countries, 2020-2022
Robertson, L. S.
10.1101/2023.10.19.23297270 — Posted: 2023-10-19
Th2 and Th17-Associated Immunopathology Following SARS-CoV-2 Breakthrough Infection in Spike-vaccinated ACE2-humanized Mice
Zhang, T., Magazine, N., McGee, M. C., Carossino, M., Veggiani, G., Kousoulas, K. G., August, A., Huang, W.
10.1101/2023.10.18.563016 — Posted: 2023-10-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).